Gene Expression Changes Induced by Genistein in the Prostate Cancer Cell Line LNCaP

Epidemiological evidence suggests that soy consumption is associated with a decreased risk of prostate cancer. The isoflavone genistein is found at high levels in soy and a large body of evidence suggests it is important in mediating the cancer preventive effects of soy. The mechanisms through which genistein acts in prostate cancer cells have not been fully defined. We used gene expression profiling to identify genes significantly modulated by low and high doses of genistein in LNCaP cells. Significant genes were identified using StepMiner analysis and significantly altered pathways with Ingenuity Pathways analysis. Genistein significantly altered expression of transcripts involved in cell growth, carcinogen defenses and steroid signaling pathways. The effects of genistein on these pathways were confirmed by directly assessing dose-related effects on LNCaP cell growth, NQO-1 enzymatic activity and PSA protein expression. Genistein produces diverse effects on gene expression that are dose-dependent and this has important implications in developing genistein as a putative prostate cancer preventive agent.

[1]  J. Ampuero,et al.  Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010 , 2011, PloS one.

[2]  Michael J. Schlicht,et al.  Use of cross species genomic profiling identifies pathways and genes differentially regulated in prostate cancer cells treated with soy protein isolates or purified genistein. , 2010, Cancer genomics & proteomics.

[3]  Jun Wang,et al.  Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV‐40 tag rats , 2009, The Prostate.

[4]  Ximing J. Yang,et al.  MEK4 function, genistein treatment, and invasion of human prostate cancer cells. , 2009, Journal of the National Cancer Institute.

[5]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[6]  R. Levy,et al.  The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. , 2009, Nutrition reviews.

[7]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[8]  J. Brooks,et al.  Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation , 2009, The Prostate.

[9]  J. Brooks,et al.  Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients , 2009, International journal of cancer.

[10]  R. Tibshirani,et al.  Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells , 2009, The Prostate.

[11]  M. Inoue,et al.  Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Saatcioglu,et al.  Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. , 2008, Oncology reports.

[13]  M. Chau,et al.  Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. , 2007, Carcinogenesis.

[14]  P. Banerjee,et al.  Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. , 2007, Carcinogenesis.

[15]  Debashis Sahoo,et al.  Extracting binary signals from microarray time-course data , 2007, Nucleic acids research.

[16]  J. Brooks,et al.  A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells , 2007, Nucleic acids research.

[17]  C. Tepper,et al.  GCP‐mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor‐dependent and ‐independent mechanisms , 2007, The Prostate.

[18]  H. Baker,et al.  Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. , 2007, Journal of NutriLife.

[19]  M. Inoue,et al.  Soy Product and Isoflavone Consumption in Relation to Prostate Cancer in Japanese Men , 2007, Cancer Epidemiology Biomarkers & Prevention.

[20]  J. Brooks,et al.  Selenomethionine induced transcriptional programs in human prostate cancer cells. , 2007, The Journal of urology.

[21]  Yoko Takahashi,et al.  Molecular signatures of soy‐derived phytochemicals in androgen‐responsive prostate cancer cells: A comparison study using DNA microarray , 2006, Molecular carcinogenesis.

[22]  I. Rowland,et al.  Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress. , 2006, Carcinogenesis.

[23]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[24]  J. Brooks,et al.  Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells , 2005, Cancer Epidemiology Biomarkers & Prevention.

[25]  Yoko Takahashi,et al.  Using DNA microarray analyses to elucidate the effects of genistein in androgen‐responsive prostate cancer cells: Identification of novel targets , 2004, Molecular carcinogenesis.

[26]  J. Brooks,et al.  Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  J. Brooks,et al.  Analysis of vitamin D‐regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays , 2004, The Prostate.

[28]  Zhengxin Wang,et al.  Modulation of androgen receptor‐dependent transcription by resveratrol and genistein in prostate cancer cells , 2004, The Prostate.

[29]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  David Botstein,et al.  Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. , 2003, Molecular biology of the cell.

[31]  Yiwei Li,et al.  Gene expression profiles of genistein-treated PC3 prostate cancer cells. , 2002, The Journal of nutrition.

[32]  L. A. Nelson,et al.  Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  Robert Tibshirani,et al.  Transcriptional programs activated by exposure of human prostate cancer cells to androgen , 2002, Genome Biology.

[34]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[35]  Ken Itoh,et al.  Enhanced Expression of the Transcription Factor Nrf2 by Cancer Chemopreventive Agents: Role of Antioxidant Response Element-Like Sequences in the nrf2 Promoter , 2002, Molecular and Cellular Biology.

[36]  J. Brooks,et al.  GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. , 2001, The American journal of pathology.

[37]  J. Brooks,et al.  Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  C. Lamartiniere,et al.  The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma. , 1999, Cancer letters.

[39]  B. Jacobsen,et al.  Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States) , 1998, Cancer Causes & Control.

[40]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  J. Fahey,et al.  Chemoprotection against cancer by phase 2 enzyme induction. , 1995, Toxicology letters.

[42]  G. Kelloff,et al.  Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. , 1995, Cancer research.

[43]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Adlercreutz,et al.  Genistein, a dietary-derived inhibitor of in vitro angiogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Santamaria,et al.  Rapid detection of inducers of enzymes that protect against carcinogens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Pinski,et al.  Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells , 2009, The Prostate.

[47]  H. Adlercreutz,et al.  Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation , 2006, The Prostate.

[48]  David Botstein,et al.  The Stanford Microarray Database , 2001, Nucleic Acids Res..

[49]  F. Sarkar,et al.  Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. , 1998, Nutrition and cancer.

[50]  S. R. Spencer,et al.  The electrophile counterattack response: protection against neoplasia and toxicity. , 1993, Advances in enzyme regulation.

[51]  W. Haenszel,et al.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.